We developed a novel nomogram for prediction of biochemical progression of disease within 1 yr after sRT in patients with BCR of PCa who underwent PSMA PET/CT imaging for restaging purposes, without evidence of metastatic disease. This evidence concerns the gene FOLH1 and posterior cortical atrophy.